Novartis Venture Fund co-led a $20.3m round for Oculis, which is developing a topical liquid that can be applied to diseases at the back of the eye.
Switzerland-based eye drop developer Oculis completed a CHF20m ($20.3m) series B round yesterday co-led by Novartis Venture Fund, a corporate venturing vehicle owned by drug producer Novartis.
The round was co-led with life sciences investment fund manager Bay City Capital and venture capital firm Pivotal BioVenture Partners. Healthcare-focused VC firm Silfurberg and VC fund Brunnur Ventures also took part in the round.
Founded in Iceland, Oculis is working on eye drops that can be applied to the eye in order…
